Non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients with NSCLC staged as T1-2N0 treated with SBRT are aimed for the study. We will include studies in which dose prescription methods and local control rate were described. Articles with at least 25 cases and a median follow-up duration of at least 12 months was included.Articles were published as full reports. Non-English reports will be excluded.The reports are permitted for centrally located tumors, or T3 or T4 tumors consisted of less than 30% of the entire study population.
Exclusion criteria
Exclusion criteria: Articles including metastasis or articles which overall survival and local control rates are not determined on a one-to-one basis will be excluded. Studies involving patients with metastatic lung tumors, postoperative recurrence or lymph node metastases, or studies restricted to elderly patients are excluded. The reports were excluded if patients are recruited for a certain property of the tumor or patients characteristics such as pathology, ground-glass opacity, operability, or interstitial pneumonia. Data that only reported outcomes for specific patient groups (e.g., operable vs. inoperable) or tumor groups (e.g., histologically proven vs. unproven) and for which no overall outcome was given are excluded. Studies including particle therapy and concurrent chemotherapy are excluded. Concurrent chemotherapy is not permitted.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Meta-regression analysis to investigate correlation coefficient between local control and overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Meta-regression analysis to investigate correlation coefficient between local control and outcomes including cancer-specific survival, distant metastases-free survival, and disease-free survival | — |
Countries
Japan
Contacts
Ofuna Chuo Hospital Radiation Oncology Center